The reduction of LEDD leads to visual dysfunction in patients with PD after STN-DBS: a randomized clinical trial.

ABSTRACT:

Background

Medication adjustment after deep brain stimulation (DBS) of the subthalamic nucleus (STN) in patients with Parkinson's disease (PD) may influence visual function. However, no clinical trials have been designed specifically to investigate this effect.

Objectives

To compare the effects of levodopa-equivalent daily dose (LEDD) reduction and non-reduction on visual function in patients with Parkinson's disease (PD) following STN-DBS.

Methods

This was a multi-center, prospective, randomized, double-blinded clinical trial. A total of 208 patients with Parkinson's disease were referred for DBS between June 2019 and July 2021 and analyzed between June 2023 and July 2023. STN-DBS was performed, and the LEDD was reduced in one study arm but not in the other. The prim

SUBMITTER: Sun J 

PROVIDER: S-EPMC11745593 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature